Pharmaceutical Cannabis

We focus on providing access to high-quality pharmaceutical products to those facing complex neurological conditions, such as drug-resistant epilepsy, helping to improve their treatment and quality of life.

Alcohol-free and sucralose-free

Convupidiol® is the first medicine with Cannabidiol (CBD) approved by ANMAT

Convupidiol® is the first pharmaceutical cannabis approved as a medicine by all five drug regulatory agencies in the region.

Constantly expanding in Latin America, Convupidiol has received approval from agencies in Argentina, Uruguay, Chile, Peru, and Ecuador.

Quality pharmaceutical cannabis for those who need it most

We collaborate with healthcare professionals, patients, and families to ensure they have access to the only reliable pharmaceutical solution for treating complex neurological conditions, such as Dravet Syndrome, Lennox- Gastaut Syndrome, and Sclerotic Tuberosis Complex, with highly positive results. Monitored by patient follow-ups since the launch date.

History

Since 2017, we have been working on the research and development of pharmaceutical products containing cannabis, at a time when pharmaceutical alternatives in international markets were nonexistent.

Our History

Equipment

With a strong commitment, we work to provide solutions for patients with drug-resistant epilepsy and other neurological conditions, ensuring appropriate and high-quality treatment.

Executive Team

Pharmaceutical Cannabis

Alcohol-free and sucralose-free

Convupidiol® is the first pharmaceutical cannabis approved as a medicine by all five drug regulatory agencies in the region.

This part of our web is reserved only for professionals as it contains information about prescription medications. Confirm you are a health professional to continue